超声造影廓清率能否用于预测肝细胞癌的微血管侵犯
本研究纳入2008年4月至2012年12月间271例肝细胞癌肝切除术前接受超声造影检查的患者,按廓清开始时间分为快速、门脉、延迟和缓慢四种廓清模式,随访3年。多因素分析显示快速廓清、肿瘤数目≥2个和肿瘤大小≥5 cm是微血管侵犯的独立术前预测因素,具有0、1、2、3个预测因素的患者复发率分别为22.6%、34.7%、57.6%和75.0%。结合肿瘤数目和大小,超声造影廓清率可能有助于识别伴有微血管侵犯的肝细胞癌患者。
要点
- 快速廓清、肿瘤数目≥2个、肿瘤大小≥5 cm是微血管侵犯的独立术前预测因素。
- 具有0、1、2、3个预测因素的患者复发率分别为22.6%、34.7%、57.6%和75.0%。
- 结合肿瘤数目和大小,超声造影廓清率可能有助于识别微血管侵犯患者。
核心结论
- 快速廓清、存在两个或以上肿瘤及肿瘤大小≥5 cm是多因素分析中微血管侵犯的独立术前预测因素;结合肿瘤数目和大小,超声造影廓清率可能有助于识别伴有微血管侵犯的肝细胞癌患者。
研究设计与样本
- 研究纳入2008年4月至2012年12月间271例因肝细胞癌接受肝切除术的患者,术前均行超声造影检查,术后随访3年,随访间隔为3个月。
关键影像表现/征象
- 根据廓清开始时间将廓清模式分为快速、门脉、延迟和缓慢四种。
- 快速廓清、存在两个或以上肿瘤及肿瘤大小≥5 cm为微血管侵犯的独立术前预测因素。
诊断标准与关键数值
- 快速廓清、肿瘤数目≥2个和肿瘤大小≥5 cm为多因素分析中微血管侵犯的独立术前预测因素。
- 复发率:无预测因素者22.6%,有1个预测因素者34.7%,有2个预测因素者57.6%,有3个预测因素者75.0%。
临床应用与阅片要点
- 阅片时可关注超声造影的廓清开始时间,将快速廓清与肿瘤数目≥2个、肿瘤大小≥5 cm结合,用于术前提示微血管侵犯可能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The objective of this study was to investigate use of the washout rate of hepatocellular carcinoma on contrast-enhanced ultrasound (CEUS) for pre-operative determination of the presence of microvascular invasion. The study included 271 patients who underwent liver resection for hepatocellular carcinoma between April 2008 and December 2012, and were examined with contrast-enhanced ultrasound before surgery. Patients were followed up at 3-mo intervals for 3 y. Four washout patterns were classified according to the start time of washout: rapid, portal, delayed and slow. Rapid washout, presence of two or more tumors and tumor size ≥5 cm were identified as independent pre-operative predictors of microvascular invasion on multivariate analysis. Recurrence rates for patients with none, one, two or three predictors were 22.6%, 34.7%, 57.6% and 75.0%, respectively. In combination with tumor number and tumor size, contrast-enhanced ultrasound washout rate may have a role in identifying hepatocellular carcinoma patients with microvascular invasion.
引用
- Zhu W, Qing X, Yan F, et al. Can the Contrast-Enhanced Ultrasound Washout Rate Be Used to Predict Microvascular Invasion in Hepatocellular Carcinoma? Ultrasound Med Biol. 2017. PMID: 28502665. doi:10.1016/j.ultrasmedbio.2017.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。